RBC Capital Sticks to Their Buy Rating for Regeneron (REGN)
RBC Capital analyst Brian Abrahams maintained a Buy rating on Regeneron (REGN – Research Report) on January 21 and set a price target of ...
RBC Capital Keeps Their Hold Rating on Neurocrine (NBIX)
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Neurocrine (NBIX – Research Report), with a ...
Fintel on MSN9h
RBC Capital Downgrades Intra-Cellular Therapies (ITCI)
Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) ...